Joint ASTCT-EBMT Basic and Translational Scientific Retreat



The American Society for Transplantation and Cellular Therapy (ASTCT) and EBMT are proud to announce the Inaugural 2022 Joint ASTCT-EBMT Basic and Translational Scientific Retreat, taking place May 25 - 27, 2022.

The Basic and Translational Scientific Retreat will be a 2.5-day conference focused on cutting edge basic and translational biology in the field. The meeting will focus on fundamental themes and novel technologies with an emphasis on unpublished and innovative science. Attendance to the meeting will be limited to 100 attendees with afternoon breaks to allow for informal networking opportunities between junior and senior attendees. The meeting will host two days of poster sessions and a best oral abstract session.

Health & Safety Registration Digital Onsite Guide Agenda

DETAILS:

May 25 – May 27, 2022
The Hythe Vail, formerly the Vail Marriott Mountain Resort
715 W. Lionshead Circle
Vail, CO 81657

HOUSING:

ASTCT and EBMT have reserved rooms at a discounted rate at The Hythe Vail. The discounted rate will be available through April 26 or until the group block is sold out. A credit card is required to hold each individual’s reservation. If you are unable to honor your reservation, you must cancel within 48 hours prior to your arrival date or your first night's room and tax will be retained.

Previously registered attendees: If you previously booked a hotel room within the ASTCT discounted room block for this event’s original dates, your hotel reservation was automatically cancelled. You will need to rebook a hotel room for the newly scheduled event, by using the housing information sent by ASTCT and EBMT. Please contact info@astct.org if you did not receive this link.


Room Rate: $169.00 (does not include local tax) plus $20 resort fee.

Information on how to make a hotel reservation will be distributed in the registration confirmation email.

Return to top

HEALTH & SAFETY:

ASTCT and EBMT are continuing to monitor recommendations from the CDC and WHO. For COVID-19 updates and what to expect at The Hythe Vail, click here. Additional information regarding COVID-19 policies for the state of Colorado are available here and for the city of Vail here. Attendees will be required to show proof of vaccination upon checking in at the registration desk. A person is considered fully vaccinated:

  • 2 weeks after their second dose in a 2-dose series, such as the Pfizer and Moderna vaccines
  • 2 weeks after a single-dose vaccine, such as Johnson & Johnson’s Janssen vaccine

Only vaccines authorized by the U.S. Food and Drug Administration (FDA) or the World Health Organization (WHO) will be accepted. These Include:

  • Moderna
  • Pfizer/ BioNTech
  • Janssen/ Johnson & Johnson
  • Oxford/ AstraZeneca
  • CoviShield (Surem Institute of India- Oxford/AstraZeneca Formulation)
  • Sinopharm- BBBIBP-CorV


TRAVEL ARRANGEMENTS:

Attendees can fly into the following airports.

  • Denver International Airport to The Hythe Vail: 2 hours 3 minutes (121 miles)
  • Eagle Vail County Regional Airport to The Hythe Vail: 37 minutes (33.9 miles)

Attendees will need to secure their own transportation arrangements to/from The Hythe Vail. The recommended shuttle company is Epic Mountain Express. On their website, select Vail/Beaver Creek under My Travel Region, then select the appropriate airport, and The Hythe Vail as the destination (alphabetized under “T”).

TARGET AUDIENCE:

The program is intended for both junior and senior members of the blood and marrow transplantation and cellular therapy field.


REGISTRATION:

Registration to this event is limited to a maximum of 100 total attendees. We are unable to accept additional registrants once the registration capacity has been met.

This conference is only for physicians and scientists who are currently practicing in the field of transplantation and cellular therapy and sponsoring companies. Please contact Angie Dahl (adahl@astct.org) if you are interested in participating as a sponsor.

Register

Type

Price

Junior Attendee Rate*

$125

Senior Attendee Rate

$250


*Junior attendees are defined as postdoctoral fellows, current fellows, and junior faculty within the first three years of appointment.

There will be no additional charge to register for the meet-the-professor sessions. Registered attendees will receive a separate communication to select the session they would like to attend closer to the meeting dates.


*PROGRAM AGENDA:

The program agenda will be broken into three main session topics – Gene editing, GVL, and GVHD. Attendees will have an extended afternoon break to network and explore Vail, Colorado. MT=US Mountain Time Zone.


Day 1: Wednesday, May 25, 2022; Gene Editing

Session Chairs: Harry Dolstra, PhD, Bruce Blazar, MD, and Leslie Kean, MD, PhD

Time

Topic

8:00 – 9:00AM MT

Optimizing and exploiting homology-directed genome editing in hematopoietic cells

Paula Cannon, PhD; University of Southern California, California, US

9:00 – 10:00AM MT

Genome Editing of the Blood: Precise and Potent Cell Based Therapies

Matthew Poretus, MD, PhD; Stanford Medicine, California, US

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

Development and Application of Targeted Epigenetic Editing

Angelo Lombardo, PhD; IRCCS Ospedale San Raffaele, Milan, IT

11:30 – 12:30PM MT

Expanding the Horizons of Genome Interventions with CRISPR Tools

Anna Cereseto, PhD; University of Trento, Trento, IT

12:30 – 4:30PM MT

Afternoon break – lunch will be available beginning at 12:30PM.

4:30 – 5:30PM MT

Best Oral Abstracts

  • Beatrice Cianciotti, PhD; Generation of human memory Stem T cells specific for tumor antigens and resistant to inhibitory signals by genome editing
  • Kayleigh Ingersoll Omdahl, PhD Candidate; Acute GVHD in liver and lungs is mediated by phenotypically analogous but transcriptionally unique T cells
  • Sawa Ito, MD, PhD; High throughput cloning reveals diverse properties of anti-HA-1 T cell receptors
  • Marc Eric Kohler, MD, PhD; A novel Adjunctive LAT-Activating CAR T (ALA-CART) platform demonstrates enhanced antigen sensitivity and in vivo efficacy against antigen-low leukemia
  • Dan Peltier, MD, PhD; Coding and Noncoding Elements of Regulatory Long Noncoding RNA of T Cells (ReLoT) Augment Allogeneic T Cell Function and T Cell Receptor Signal Transduction

5:30 – 6:30PM MT

Poster Hall + Networking Hour

6:30 – 7:30PM MT
(Dinner Session)

Extending the Applicability of Immune Effector Therapies

Helen Heslop, MD, DSc; Baylor College of Medicine, Texas, US

Day 1 concludes

Day 2: Thursday, May 26, 2022; Graft-versus-Leukemia

Session Chairs: Chiara Bonini, MD and Warren Shlomchik, MD

Time

Topic

8:00 – 9:00AM MT

Biological Mechanisms and Personalized Therapy of Post-Transplantation Leukemia Relapses

Luca Vago, MD, PhD, San Raffaele Scientific Institute, Milan, IT

9:00 – 10:00AM MT

Mechanisms of GVL Resistance

Warren Shlomchik, MD; University of Pittsburgh, Pennsylvania, US

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

Immune Escape Mechanisms Causing AML Relapse After Allo-HCT

Robert Zeiser, MD; University of Freiburg, Breisgau, DE

11:30 – 12:30PM MT

Treating AML with Engineered T cells: Identifying Obstacles to Efficacy and Designing Solutions

Philip Greenberg, MD; Fred Hutchinson Cancer Research Center, Washington, US

12:30 – 4:30PM MT

Afternoon break – lunch will be available beginning at 12:30PM.

4:30 – 5:30PM MT

Meet-the-Professor Session

5:30 – 6:30PM MT

Poster Hall + Networking Hour

6:30 – 7:30PM MT
(Dinner Session)

Transcriptional Networks in Tumour-Infiltrating T Cells

Anjana Rao, PhD; La Jolla Institute for Immunology, California, US

Day 2 concludes

Day 3: Friday, May 27, 2022; Graft-versus-Host Disease

Session Chairs: Pavan Reddy, MD and Nicolaus Kröger, MD

Time

Topic

8:00 – 9:00AM MT

Tissue is the Issue: Insights Into GI Tract Immune Destruction From Single Cell Analysis of Inflammatory Bowel Disease

Leslie Kean, MD, PhD; Boston Children's Hospital, Massachusetts, US

9:00 – 10:00AM MT

Next Challenges in GHVD: From Bedside back to the Bench

Gerard Socié, MD, PhD; Hôpital Saint-Louis, Paris, FR

10:00 – 10:30AM MT

Break

10:30 – 11:30AM MT

The Microbiome and Graft vs Host Disease

Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, New York, US

11:30 – 1:00PM MT

Best Oral Abstracts

  • Laura McLaughlin, MD; JAK Inhibitors Facilitate Hematopoietic Cell Engraftment Following Allogeneic BMT
  • Katherine Oravecz-Wilson; Characterization of target organ intrinsic pathways that regulate their sensitivity to pathogenic T cells
  • Jonathan Peled, MD, PhD; Nutrition as a predictor of microbiome injury in allo-HCT
  • Kevin Quann, MD, PhD; TCF-1+ T Cells Sustain Alloimmune Responses in Graft-vs-Host Disease 
  • Keisuke Seike, PhD; Mitochondrial complex II controls naive T cell functions
  • Symeon Theocharidis, PhD Candidate; Distinct metabolic profiles for effector and regulatory subsets of human alloreactive CD4 T cells
  • Victor Tkachev, PhD; Uncovering a novel evolutionary-conserved mechanism to control GI GVHD: Notch pathway blockade leads to beta1/beta7 integrin competition and resulting failure of GI tract infiltration by effector T cells.

1:00 – 1:15PM MT

Closing remarks; conference wrap up

Day 3 concludes

*Sessions and speakers are subject to change.

Return to top

Sponsor Opportunities

If you are interested in sponsoring this event, please contact Angie Dahl.

Thank you to our presenting sponsors